Assays for TIMP2 having improved performance in biological samples

Patent metadata

Field	Value
Publication number	US-9879091-B2
Application number	US-201414910661-A
Country	US
Kind code	B2
Filing date	Aug 7, 2014
Priority date	Aug 7, 2013
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.

First claim

We claim:

1. A method for determining the presence or amount of human TIMP2 in a biological sample, comprising:
performing an immunoassay on the biological sample with a first monoclonal antibody and a second monoclonal antibody which together form sandwich complexes with human TIMP2, wherein the immunoassay provides a detectable signal that is related to the presence or amount of human TIMP2 in the biological sample bound in the sandwich complexes; and
relating the detectable signal to the presence or amount of human TIMP2 in the biological sample, wherein one or both of the first monoclonal antibody and second monoclonal antibody—is a monoclonal antibody that binds with an affinity of at least 10 8 M −1 to a polypeptide, wherein the sequence of said polypeptide consists of a sequence selected from the group consisting of:

(SEQ ID NO: 1)

QAFCNADVVIRAKAVSEKEVD,

(SEQ ID NO: 2)

IYGNPIKRIQYEIKQI,

(SEQ ID NO: 3)

YEIKQIKMFKGPEKDIEFIYTAPSSAVC

GVSLDVGGKKEYLIAGKAEGDG,

(SEQ ID NO: 4)

YEIKQIKMFKGPEKDIEFIYTAPSSAV,

(SEQ ID NO: 5)

EFIYTAPSSAVCGVS,

(SEQ ID NO: 6)

TAPSSAVCGVSLDVGGKKEYLIAGKA,

(SEQ ID NO: 7)

SLDVGGKKEYLIAGKAEGDGK,

(SEQ ID NO: 8)

SSPDECLWMDWVTEKNINGHQ,

and

(SEQ ID NO: 9)

CAWYRGAAPPKQEFLDIEDP.

2. A method according to claim 1 , wherein the minimum detectable concentration of TIMP-2 in the immunoassay is 10 ng/mL or less.

3. A method according to claim 2 , wherein the immunoassay is performed in a lateral flow format.

4. A method according to claim 2 , wherein the immunoassay is an in vitro diagnostic.

5. A method according to claim 4 , wherein the immunoassay is performed by applying the human patient sample to a disposable test device, and the detectable signal is obtained by inserting the disposable test device into an analytical instrument, wherein the sandwich complexes comprising the first and second antibodies are immobilized for detection in a predetermined zone of the disposable test device, and wherein the analytical instrument detects the immobilized sandwich complexes to provide the detectable signal.

6. A method according to claim 2 , wherein the first antibody is conjugated to a signal development element.

7. A method according to claim 6 , wherein the first antibody forms a reaction mixture with the human patient sample, and the human patient sample is applied to the disposable test device by applying the reaction mixture to the disposable test device.

8. A method according to claim 6 , wherein the second antibody is immobilized at the predetermined zone of a solid support.

9. A method according to claim 2 , wherein each of the first and second antibodies is a rabbit, mouse, chicken, goat, sheep, donkey, human, llama or camelid antibody.

10. A method according to claim 2 , wherein each of the first and second antibodies is a rabbit antibody.

11. A method according to claim 2 , wherein each of the first and second antibodies is a monoclonal antibody that binds with an affinity of at least 10 8 M −1 to a polypeptide, wherein the sequence of said polypeptide consists of a sequence selected from the group consisting of:

(SEQ ID NO: 1)

QAFCNADVVIRAKAVSEKEVD,

(SEQ ID NO: 2)

IYGNPIKRIQYEIKQI,

(SEQ ID NO: 3)

YEIKQIKMFKGPEKDIEFIYTAPSSAV

CGVSLDVGGKKEYLIAGKAEGDG,

(SEQ ID NO: 4)

YEIKQIKMFKGPEKDIEFIYTAPSSAV,

(SEQ ID NO: 5)

EFIYTAPSSAVCGVS,

(SEQ ID NO: 6)

TAPSSAVCGVSLDVGGKKEYLIAGKA,

(SEQ ID NO: 7)

SLDVGGKKEYLIAGKAEGDGK,

(SEQ ID NO: 8)

SSPDECLWMDWVTEKNINGHQ,

and

(SEQ ID NO: 9)

CAWYRGAAPPKQEFLDIEDP.

Assignees

• Astute Medical Inc

Inventors

• Vijayendran Ravi A
• Venkatasubbarao Srivatsa

Classifications

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• G01N33/577

  involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)} · CPC title

• C07K16/38 Primary

  against protease inhibitors of peptide structure · CPC title

• G01N2333/8146

  Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP · CPC title